Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-01-04Clinical Trial Update: Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia [Phase 2]
Phase 2 trial update evaluating nilotinib and imatinib mesylate in early chronic phase chronic myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2022-01-04Clinical Trial Update: Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate [NA]
Clinical trial update of imatinib mesylate for various myeloproliferative and related neoplasms including CMML, CML, polycythemia vera, hype…
-
FDA approval · 2022-01-03FDA Approved: DASATINIB — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for dasatinib (DASATINIB) filed by Apotex Corp. The action confirms regulatory approval related to t…
-
CLINICAL_TRIALS trial_result · 2021-12-30Clinical Trial Update: Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors [Phase 4]
Phase 4 safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients previously treated with…
-
CLINICAL_TRIALS trial_result · 2021-11-26Clinical Trial Update: A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia [Phase 3]
Phase 3 trial comparing ponatinib vs nilotinib in chronic phase chronic myeloid leukemia has been terminated; results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-11-23FDA Approved: DASATINIB — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s generic dasatinib (DASATINIB) under an Original Application (ANDA) for use in Philadelphia chromosome–positive l…
-
CLINICAL_TRIALS trial_result · 2021-11-05Clinical Trial Update: European Stop Tyrosine Kinase Inhibitor Study [Phase 3]
A Phase 3 clinical trial update for a study on tyrosine kinase inhibitors in chronic myeloid leukemia has completed.
-
FDA approval · 2021-10-29FDA Approved: SCEMBLIX — Original Application (Novartis Pharmaceuticals Corporation)
The FDA approved SCEMBLIX (asciminib) from Novartis as an original approval for chronic myeloid leukemia. It represents a first-in-class tar…
-
CLINICAL_TRIALS trial_result · 2021-10-28Clinical Trial Update: Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response [Phase 2]
Phase 2 trial investigating imatinib mesylate with zoledronic acid in chronic myeloid leukemia patients in cytogenetic response without mole…
-
FDA approval · 2021-09-23FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for TASIGNA (nilotinib) from Novartis.
-
CLINICAL_TRIALS trial_result · 2021-08-17Clinical Trial Update: Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 [NA]
A completed bosutinib treatment extension study for CML patients who previously participated in related bosutinib trials; results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-22Clinical Trial Update: An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha [Phase 2]
Phase 2 extension study evaluating efficacy and safety of STI571 in chronic myeloid leukemia patients refractory to or intolerant of interfe…
-
CLINICAL_TRIALS trial_result · 2021-07-14Clinical Trial Update: Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase [Phase 2]
Phase 2 trial evaluating LBH589B in adult patients with refractory chronic myeloid leukemia in accelerated or blast phase; study terminated …
-
CLINICAL_TRIALS trial_result · 2021-07-01Clinical Trial Update: An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment [Phase 4]
Phase 4 exploratory trial evaluating adverse event improvement when chronic myeloid leukemia patients switch from imatinib to nilotinib.
-
FDA approval · 2021-06-29FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for dasatinib submitted by Prasco Laboratories, enabling continued or expanded marketing under a…
-
CLINICAL_TRIALS trial_result · 2021-06-29Clinical Trial Update: A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies [Phase 1, Phase 2]
A Phase 1/2 study of oral AMN107 (imatinib) in adults with chronic myeloid leukemia and other hematologic malignancies has completed enrollm…
-
CLINICAL_TRIALS trial_result · 2021-06-25Clinical Trial Update: An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis [Phase 2]
Phase 2 extension study evaluating safety and anti-leukemic effects of imatinib mesylate in Philadelphia chromosome-positive chronic myeloid…
-
CLINICAL_TRIALS trial_result · 2021-06-14Clinical Trial Update: Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses [Phase 2]
Phase 2 dose-ranging trial of ponatinib in patients with resistant chronic phase chronic myeloid leukemia to characterize efficacy and safet…
-
CLINICAL_TRIALS trial_result · 2021-06-14Clinical Trial Update: Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies [NA]
A completed clinical trial evaluating intensity modulated total marrow irradiation (IM-TMI) for advanced hematologic malignancies, with resu…
-
CLINICAL_TRIALS trial_result · 2021-06-14Clinical Trial Update: A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) [Phase 4]
Phase 4 trial update evaluating dasatinib as first-line therapy for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) complete…
-
CLINICAL_TRIALS trial_result · 2021-05-20Clinical Trial Update: Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations [Phase 4]
A Phase 4 clinical trial investigating nilotinib in Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase patients with…
-
FDA approval · 2021-05-14FDA Approved: BOSULIF — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for Bosulif (bosutinib) submitted by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2021-05-12Clinical Trial Update: Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment [Phase 2]
Phase 2 clinical trial evaluating the value of adding pioglitazone to treatment in chronic myeloid leukemia with BCR-ABL positivity.
-
CLINICAL_TRIALS trial_result · 2021-04-15Clinical Trial Update: Allogeneic Stem Cell Transplantation for Children With CML [Phase 2, Phase 3]
Phase 2/3 trial updating outcomes of allogeneic stem cell transplantation in children with chronic myeloid leukemia; study completed.
-
FDA approval · 2021-03-25FDA Approved: IMATINIB — Supplemental Application (Dr.Reddy's Laboratories Inc)
FDA approved a supplemental application for imatinib from Dr. Reddy's Laboratories, supporting an update to the drug's labeling under the AN…